Literature DB >> 8393933

Two-dimensional nuclear magnetic resonance analysis of a labeled peptide bound to a class II major histocompatibility complex molecule.

P C Driscoll1, J D Altman, J J Boniface, K Sakaguchi, P A Reay, J G Omichinski, E Appella, M M Davis.   

Abstract

The formation of peptide/major histocompatibility complex (MHC) complexes and their subsequent recognition by T cells is a pivotal event in the initiation of an immune response. While X-ray crystal structures are now available for class I MHC/peptide complexes, little detailed structural information is known about the class II MHC equivalent, and there are no solution structure data for either. A 16 amino acid residue moth cytochrome c peptide (residues 88 to 103) was 13C-labeled for two-dimensional isotope-edited NMR analysis. The peptide was labeled either selectively in the methyl groups of alanine residues or uniformly at every carbon position, and bound to unlabeled soluble mouse I-Ek class II MHC molecules. Although alpha-helical in the native cytochrome c protein and with no uniform structure in solution, the peptide is bound to the I-Ek molecule with the alpha-carbon atoms of the 11 C-terminal residues held in the binding groove. This indicates that the class II MHC peptide binding site is somewhat larger than that of class I MHC molecules (> or = 11 amino acid residues versus 8 to 10 amino acid residues), consistent with recent data on eluted peptides. Despite the large size of the complex (approximately 70 kDa), nuclear Overhauser effects are clearly detectable between peptide side-chains and the MHC molecule. Indications of the buried or exposed nature of particular side-chains within the bound peptide are derived from the NMR data and these are used together with information from previous biological studies to propose a crude model of the interaction of the peptide with the groove of the MHC molecule. We find no evidence for a conformational change in the peptide/MHC complex in the spectra at pH 5.0 versus pH 7.0, despite a 40-fold faster on-rate for the peptide at the lower pH value.

Entities:  

Mesh:

Substances:

Year:  1993        PMID: 8393933     DOI: 10.1006/jmbi.1993.1394

Source DB:  PubMed          Journal:  J Mol Biol        ISSN: 0022-2836            Impact factor:   5.469


  6 in total

1.  Differing processing requirements of four recombinant antigens containing a single defined T-cell epitope for presentation by major histocompatibility complex class II.

Authors:  L Colledge; M Y Sun ; W Lin; C C Blackburn; P A Reay
Journal:  Immunology       Date:  2001-07       Impact factor: 7.397

2.  Stability of empty and peptide-loaded class II major histocompatibility complex molecules at neutral and endosomal pH: comparison to class I proteins.

Authors:  Z Reich; J D Altman; J J Boniface; D S Lyons; H Kozono; G Ogg; C Morgan; M M Davis
Journal:  Proc Natl Acad Sci U S A       Date:  1997-03-18       Impact factor: 11.205

3.  Formation of functional peptide complexes of class II major histocompatibility complex proteins from subunits produced in Escherichia coli.

Authors:  J D Altman; P A Reay; M M Davis
Journal:  Proc Natl Acad Sci U S A       Date:  1993-11-01       Impact factor: 11.205

4.  Bidirectional binding of invariant chain peptides to an MHC class II molecule.

Authors:  Sebastian Günther; Andreas Schlundt; Jana Sticht; Yvette Roske; Udo Heinemann; Karl-Heinz Wiesmüller; Günther Jung; Kirsten Falk; Olaf Rötzschke; Christian Freund
Journal:  Proc Natl Acad Sci U S A       Date:  2010-11-29       Impact factor: 11.205

5.  Structural basis of cytochrome c presentation by IE(k).

Authors:  Daved H Fremont; Shaodong Dai; Herbert Chiang; Frances Crawford; Philippa Marrack; John Kappler
Journal:  J Exp Med       Date:  2002-04-15       Impact factor: 14.307

6.  Evidence for a conformational change in a class II major histocompatibility complex molecule occurring in the same pH range where antigen binding is enhanced.

Authors:  J J Boniface; D S Lyons; D A Wettstein; N L Allbritton; M M Davis
Journal:  J Exp Med       Date:  1996-01-01       Impact factor: 14.307

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.